J C Levy1, M J Davies2, R R Holman3. 1. Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, UK. Electronic address: jonathan.levy@ocdem.ox.ac.uk. 2. University of Leicester, Diabetes Research Centre, Leicester, UK. 3. Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, UK. Electronic address: rury.holman@dtu.ox.ac.uk.
Abstract
AIMS: Hypoglycaemia is a significant risk in insulin treated type 2 diabetes and has been associated with future risk of cardiovascular events. We compared the frequency of low-glucose events using continuous glucose monitoring (CGM) with that of self-reported hypoglycemic events at the end of the first and third years of the Treating to Target in Type 2 Diabetes Trial (4-T), which compared biphasic, prandial and basal insulin regimens added to sulfonylurea and metformin. METHODS: CGM using a Medtronic Gold system was performed in a subgroup of 4-T participants. CGM detected low-glucose events were defined at thresholds of ≤3.0 (CGM3.0) and ≤2.2 (CGM2.2) mmol/l. RESULTS: Of the 110 participants, 106 and 70 had CGM analysable data at the end of years 1 and 3 respectively. In both years, the frequency of CGM detected low glucose events was several fold higher than that of self-reported hypoglycaemia (symptoms with blood glucose less than 3.1mmol/l [<56mg/dl]). At the end of the first year, CGM3.0 and CGM2.2 mean (95%CI) event frequencies, expressed at events per participant per year, were 120 (85, 155) and 41 (21, 61) compared with 17 (8, 29) self-reported events during CGM, each p=0.001. The disparity at the end of the third year was similar. CONCLUSIONS: These data demonstrate the likely under-reporting of hypoglycaemia and of potential hypoglycaemia unawareness in clinical trials. The clinical implications of these findings need to be explored further (ISRCTN No ISRCTN51125379).
AIMS: Hypoglycaemia is a significant risk in insulin treated type 2 diabetes and has been associated with future risk of cardiovascular events. We compared the frequency of low-glucose events using continuous glucose monitoring (CGM) with that of self-reported hypoglycemic events at the end of the first and third years of the Treating to Target in Type 2 Diabetes Trial (4-T), which compared biphasic, prandial and basal insulin regimens added to sulfonylurea and metformin. METHODS:CGM using a Medtronic Gold system was performed in a subgroup of 4-T participants. CGM detected low-glucose events were defined at thresholds of ≤3.0 (CGM3.0) and ≤2.2 (CGM2.2) mmol/l. RESULTS: Of the 110 participants, 106 and 70 had CGM analysable data at the end of years 1 and 3 respectively. In both years, the frequency of CGM detected low glucose events was several fold higher than that of self-reported hypoglycaemia (symptoms with blood glucose less than 3.1mmol/l [<56mg/dl]). At the end of the first year, CGM3.0 and CGM2.2 mean (95%CI) event frequencies, expressed at events per participant per year, were 120 (85, 155) and 41 (21, 61) compared with 17 (8, 29) self-reported events during CGM, each p=0.001. The disparity at the end of the third year was similar. CONCLUSIONS: These data demonstrate the likely under-reporting of hypoglycaemia and of potential hypoglycaemia unawareness in clinical trials. The clinical implications of these findings need to be explored further (ISRCTN No ISRCTN51125379).
Authors: Iram Ahmad; Leila R Zelnick; Zona Batacchi; Nicole Robinson; Ashveena Dighe; Jo-Anne E Manski-Nankervis; John Furler; David N O'Neal; Randie Little; Dace Trence; Irl B Hirsch; Nisha Bansal; Ian H de Boer Journal: Clin J Am Soc Nephrol Date: 2019-04-17 Impact factor: 8.237
Authors: Emidio Scarpellini; Joris Arts; George Karamanolis; Anna Laurenius; Walter Siquini; Hidekazu Suzuki; Andrew Ukleja; Andre Van Beek; Tim Vanuytsel; Serhat Bor; Eugene Ceppa; Carlo Di Lorenzo; Marloes Emous; Heinz Hammer; Per Hellström; Martine Laville; Lars Lundell; Ad Masclee; Patrick Ritz; Jan Tack Journal: Nat Rev Endocrinol Date: 2020-05-26 Impact factor: 43.330
Authors: René Rodríguez-Gutiérrez; Alejandro Salcido-Montenegro; José Gerardo González-González; Rozalina G McCoy Journal: BMJ Open Diabetes Res Care Date: 2021-04
Authors: Patrick Divilly; Natalie Zaremba; Zeinab Mahmoudi; Uffe Søholm; Daniel J Pollard; Melanie Broadley; Evertine J Abbink; Bastiaan de Galan; Ulrik Pedersen-Bjergaard; Eric Renard; Mark Evans; Jane Speight; Alan Brennan; Rory J McCrimmon; Matthias Müllenborn; Simon Heller; Alexander Seibold; Julia K Mader; Stephanie A Amiel; Frans Pouwer; Pratik Choudhary Journal: Diabet Med Date: 2022-06-22 Impact factor: 4.213